Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...

Such models are not only useful for understanding the underlying causes of disease and identifying new drug targets, but also for drug screening. Patient-derived iPSC models are being used to ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), ...

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms ... Fossati’s lab to identify ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report ... with a $8.50 average price target. The company has a one-year high of ...

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, United States ...

Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are ...